Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: A randomized, prospective clinical investigation

被引:7
作者
Gibson, Michael C. [1 ]
Krucoff, Mitchell [2 ]
Fischell, David [3 ]
Fischell, Tim A. [4 ]
Keenan, David [3 ]
Abueg, Cassandra [1 ]
Patel, Charmaine [1 ]
Holmes, David [5 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02215 USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Angel Med Syst, Shrewsbury Township, NJ USA
[4] Heart Inst Borgess, Kalamazoo, MI USA
[5] Mayo Clin, Rochester, MN USA
关键词
ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; EMERGENCY MEDICAL-SERVICES; TO-BALLOON TIMES; INTRACARDIAC ELECTROGRAM; NATIONAL REGISTRY; MORTALITY; TRENDS; DELAY; ANGIOPLASTY;
D O I
10.1016/j.ahj.2014.05.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Significant improvements in door-to-balloon times have led to a reduction in mortality in ST-segment elevation myocardial infarction; however, mean symptom-to-door times remain at 2 to 3 hours. An intracardiac electrogram monitoring device may be beneficial in high-risk patients by alerting them to rapidly progressive ST-segment changes indicative of acute coronary occlusion. The Cardiosaver and DETECT phase I clinical studies demonstrated the safety, feasibility, and potential benefit of using an intracardiac electrogram monitoring device to alert the patient to seek medical attention. The goal of the randomized, prospective ALERTS Trial (Clinicaltrials.gov no. NCT00781118) is to evaluate the efficacy of an implantable monitoring device (IMD) in reducing the composite of either cardiac or unexplained death, new Q-wave myocardial infarction, or symptom-to-door time of >2 hours for confirmed thrombotic events. The IMD alerts the patient in real time when ST-segment deviation from a personalized baseline exceeds the trigger threshold. The trial is designed to enroll high-risk post-acute coronary syndrome patients or patients with previous multivessel coronary artery bypass surgery. All patients have the IMD implanted, with 1:1 unblinded randomization to the alerting feature being either turned on versus turned off for the first 6 months. Randomization occurs at the first follow-up visit, 7 to 14 days after the implantation of the IMD. Subjects then return for follow-up visits at months 1, 3, and 6 and thereafter every 6 months until closure of the investigational device exemption. Subjects who cannot be implanted successfully or who have the device explanted are removed from the study and followed up for a minimum of 30 days post-procedure. If a subject experiences a device-related complication and/or adverse experience, the subject is followed up until resolution or until the condition becomes stable and no further change is anticipated.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 33 条
[1]  
[Anonymous], 1988, J AM COLL CARDIOL, V12, pA3
[2]  
[Anonymous], 1986, Lancet, V1, P397
[3]   ELECTROCARDIOGRAPHIC EVOLUTION OF POSTERIOR ACUTE MYOCARDIAL-INFARCTION - IMPORTANCE OF EARLY PRECORDIAL ST-SEGMENT DEPRESSION [J].
BODEN, WE ;
KLEIGER, RE ;
GIBSON, RS ;
SCHWARTZ, DJ ;
SCHECHTMAN, KB ;
CAPONE, RJ ;
ROBERTS, R .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (08) :782-787
[4]   Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour [J].
Boersma, E ;
Maas, ACP ;
Deckers, JW ;
Simoons, ML .
LANCET, 1996, 348 (9030) :771-775
[5]   Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients [J].
Brown, AL ;
Mann, NC ;
Daya, M ;
Goldberg, MR ;
Meischke, H ;
Taylor, J ;
Smith, K ;
Osganian, S ;
Cooper, L .
CIRCULATION, 2000, 102 (02) :173-+
[6]   Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [J].
Burgess, David C. ;
Hunt, David ;
Li, LiPing ;
Zannino, Diana ;
Williamson, Elizabeth ;
Davis, Timothy M. E. ;
Laakso, Markku ;
Kesaniemi, Y. Antero ;
Zhang, Jun ;
Sy, Raymond W. ;
Lehto, Seppo ;
Mann, Stewart ;
Keech, Anthony C. .
EUROPEAN HEART JOURNAL, 2010, 31 (01) :92-99
[7]   Use of Emergency Medical Services in acute myocardial infarction and subsequent quality of care - Observations from the National Registry of Myocardial Infarction 2 [J].
Canto, JG ;
Zalenski, RJ ;
Ornato, JP ;
Rogers, WJ ;
Kiefe, CI ;
Magid, D ;
Shlipak, MG ;
Frederick, PD ;
Lambrew, CG ;
Littrell, KA ;
Barron, HV .
CIRCULATION, 2002, 106 (24) :3018-3023
[8]  
Chew Derek P, 2002, J Invasive Cardiol, V14 Suppl A, p3A
[9]   Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study [J].
Davis, TME ;
Fortun, P ;
Mulder, J ;
Davis, WA ;
Bruce, DG .
DIABETOLOGIA, 2004, 47 (03) :395-399
[10]   Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction - Every minute of delay counts [J].
De Luca, G ;
Suryapranata, H ;
Ottervanger, JP ;
Antman, EM .
CIRCULATION, 2004, 109 (10) :1223-1225